CMS-HCC Risk Adjustment · Retired V24 Model 72 Codes
V24 HCC 48 (Archived Category) ICD-10-CM
HCC 48 is a payment category of the retired CMS-HCC V24 model, which last determined Medicare Advantage payment in 2025. The 72 ICD-10-CM codes below are its final mappings, kept for lookback analysis and RADV audit reference. Each code shows where it maps in the live V28 model; 39 of them no longer risk-adjust at all.
✗ Retired model · not used for current Medicare Advantage paymentLast paid PY 2025 · kept for lookback and RADV reference
72
ICD-10-CM Codes
33
Still Risk-Adjust in V28
39
No V28 Successor
PY 2025
Last Paid Year
CMS-HCC V24
Archived Codes of V24 HCC 48 72 codes
72 of 72 shown
- C94.6 Myelodysplastic disease, not elsewhere classified now HCC 19
- D45 Polycythemia vera now HCC 23
- D47.1 Chronic myeloproliferative disease now HCC 21
- D47.3 Essential (hemorrhagic) thrombocythemia now HCC 23
- D47.9 Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified now HCC 21
- D47.Z1 Post-transplant lymphoproliferative disorder (PTLD) now HCC 21
- D47.Z2 Castleman disease now HCC 21
- D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue now HCC 21
- D55.0 Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency no V28 successor
- D55.1 Anemia due to other disorders of glutathione metabolism no V28 successor
- D55.21 Anemia due to pyruvate kinase deficiency no V28 successor
- D55.29 Anemia due to other disorders of glycolytic enzymes no V28 successor
- D55.3 Anemia due to disorders of nucleotide metabolism no V28 successor
- D55.8 Other anemias due to enzyme disorders no V28 successor
- D55.9 Anemia due to enzyme disorder, unspecified no V28 successor
- D56.0 Alpha thalassemia no V28 successor
- D56.1 Beta thalassemia now HCC 108
- D56.2 Delta-beta thalassemia now HCC 108
- D56.4 Hereditary persistence of fetal hemoglobin [HPFH] no V28 successor
- D56.5 Hemoglobin E-beta thalassemia now HCC 108
- D56.8 Other thalassemias no V28 successor
- D57.3 Sickle-cell trait no V28 successor
- D58.0 Hereditary spherocytosis no V28 successor
- D58.1 Hereditary elliptocytosis no V28 successor
- D58.2 Other hemoglobinopathies no V28 successor
- D58.8 Other specified hereditary hemolytic anemias no V28 successor
- D58.9 Hereditary hemolytic anemia, unspecified no V28 successor
- D64.0 Hereditary sideroblastic anemia now HCC 109
- D64.1 Secondary sideroblastic anemia due to disease now HCC 109
- D64.2 Secondary sideroblastic anemia due to drugs and toxins no V28 successor
- D64.3 Other sideroblastic anemias now HCC 109
- D65 Disseminated intravascular coagulation [defibrination syndrome] no V28 successor
- D68.00 Von Willebrand disease, unspecified now HCC 112
- D68.01 Von Willebrand disease, type 1 now HCC 112
- D68.020 Von Willebrand disease, type 2A now HCC 112
- D68.021 Von Willebrand disease, type 2B now HCC 112
- D68.022 Von Willebrand disease, type 2M now HCC 112
- D68.023 Von Willebrand disease, type 2N now HCC 112
- D68.029 Von Willebrand disease, type 2, unspecified now HCC 112
- D68.03 Von Willebrand disease, type 3 now HCC 112
- D68.04 Acquired von Willebrand disease now HCC 112
- D68.09 Other von Willebrand disease now HCC 112
- D68.1 Hereditary factor XI deficiency now HCC 112
- D68.2 Hereditary deficiency of other clotting factors now HCC 112
- D68.311 Acquired hemophilia now HCC 112
- D68.312 Antiphospholipid antibody with hemorrhagic disorder no V28 successor
- D68.318 Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors no V28 successor
- D68.32 Hemorrhagic disorder due to extrinsic circulating anticoagulants no V28 successor
- D68.4 Acquired coagulation factor deficiency no V28 successor
- D68.51 Activated protein C resistance no V28 successor
- D68.52 Prothrombin gene mutation no V28 successor
- D68.59 Other primary thrombophilia no V28 successor
- D68.61 Antiphospholipid syndrome no V28 successor
- D68.62 Lupus anticoagulant syndrome no V28 successor
- D68.69 Other thrombophilia no V28 successor
- D68.8 Other specified coagulation defects no V28 successor
- D68.9 Coagulation defect, unspecified no V28 successor
- D69.0 Allergic purpura no V28 successor
- D69.1 Qualitative platelet defects now HCC 112
- D69.2 Other nonthrombocytopenic purpura no V28 successor
- D69.3 Immune thrombocytopenic purpura now HCC 112
- D69.41 Evans syndrome now HCC 112
- D69.42 Congenital and hereditary thrombocytopenia purpura now HCC 112
- D69.49 Other primary thrombocytopenia now HCC 112
- D69.6 Thrombocytopenia, unspecified no V28 successor
- D69.8 Other specified hemorrhagic conditions no V28 successor
- D69.9 Hemorrhagic condition, unspecified no V28 successor
- D75.821 Non-immune heparin-induced thrombocytopenia no V28 successor
- D75.822 Immune-mediated heparin-induced thrombocytopenia no V28 successor
- D75.828 Other heparin-induced thrombocytopenia syndrome no V28 successor
- D75.829 Heparin-induced thrombocytopenia, unspecified no V28 successor
- D75.84 Other platelet-activating anti-PF4 disorders now HCC 112
Questions About This Archived Category
Is V24 HCC 48 still paid?
No. The CMS-HCC V24 model last determined Medicare Advantage payment in 2025; from payment year 2026 the V28 model pays 100% of the risk score. This page exists for lookback analysis and RADV audit periods that predate the transition.
Where did these codes go in V28?
Each row above names the code's live V28 category, or marks it as having no V28 successor. The category-level picture, with destination counts for every V24 category, is on V24 to V28: What Changed.
Related References
Source: Centers for Medicare & Medicaid Services, Payment Year 2026 risk adjustment mapping and model software releases (CMS-HCC V28; CMS-HCC V24 from the last published V24 mappings, payment year 2025), applied to the FY 2026 ICD-10-CM code set. ICD List is not affiliated with CMS.
